These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7769051)

  • 1. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.
    Lockwood GM; Pinkerton SM; Barlow DH
    Hum Reprod; 1995 Feb; 10(2):293-8. PubMed ID: 7769051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
    Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
    Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer.
    Goldman JA; Dicker D; Feldberg D; Ashkenazi J; Voliowich I
    Hum Reprod; 1994 Feb; 9(2):226-8. PubMed ID: 8027276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study.
    El-Nemr A; Bhide M; Khalifa Y; Al-Mizyen E; Gillott C; Lower AM; Al-Shawaf T; Grudzinskas JG
    Eur J Obstet Gynecol Reprod Biol; 2002 Jul; 103(2):140-5. PubMed ID: 12069736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal nafarelin versus buserelin (short protocol) for controlled ovarian hyperstimulation before in vitro fertilization: a prospective clinical trial.
    Avrech OM; Goldman GA; Pinkas H; Amit S; Neri A; Zukerman Z; Ovadia J; Fisch B
    Gynecol Endocrinol; 1996 Jun; 10(3):165-70. PubMed ID: 8862491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
    Biljan MM; Mahutte NG; Dean N; Hemmings R; Bissonnette F; Tan SL
    Fertil Steril; 1998 Dec; 70(6):1063-9. PubMed ID: 9848296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between nafarelin and leuprolide acetate for in vitro fertilization: preliminary clinical study.
    Dantas ZN; Vicino M; Balmaceda JP; Asch RH; Stone SC
    Fertil Steril; 1994 Apr; 61(4):705-8. PubMed ID: 8150114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of nafarelin in assisted reproductive technology: a meta-analysis.
    Wong JM; Forrest KA; Snabes SZ; Zhao SZ; Gersh GE; Kennedy SH
    Hum Reprod Update; 2001; 7(1):92-101. PubMed ID: 11212082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study.
    Dada T; Salha O; Baillie HS; Sharma V
    Hum Reprod; 1999 Feb; 14(2):288-93. PubMed ID: 10099965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nafarelin acetate for pituitary down-regulation in in vitro fertilization. Comparison of two dosages.
    Yuzpe AA; Nisker JA; Kaplan BR; Tummon IS; Auckland J
    J Reprod Med; 1995 Feb; 40(2):83-8. PubMed ID: 7738933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midluteal buserelin is superior to early follicular phase buserelin in combined gonadotropin-releasing hormone analog and gonadotropin stimulation in in vitro fertilization.
    Urbancsek J; Witthaus E
    Fertil Steril; 1996 May; 65(5):966-71. PubMed ID: 8612858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of buserelin and nafarelin in IVF cycles and in subsequent frozen-thawed embryo transfer cycles.
    Simberg N; Tulppala M; Husa LM; Tiitinen A
    Acta Obstet Gynecol Scand; 1998 Sep; 77(8):854-9. PubMed ID: 9776601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin-releasing hormone agonist in in vitro fertilization--a prospective randomized study.
    Shaker AG; Pittrof R; Zaidi J; Bekir J; Kyei-Mensah A; Tan SL
    Fertil Steril; 1995 Oct; 64(4):791-5. PubMed ID: 7672152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of a short regimen of buserelin, a gonadotrophin-releasing hormone agonist, and human menopausal gonadotrophin in assisted conception cycles.
    Owen EJ; Davies MC; Kingsland CR; Jacobs HS; Mason BA
    Hum Reprod; 1989 Oct; 4(7):749-53. PubMed ID: 2514192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum placental protein 14 concentrations are similar in the first trimester pregnancies of women after pituitary down-regulation with a gonadotrophin-releasing hormone agonist and normal cycles with frozen embryo transfers.
    Miettinen T; Tiitinen A; Koistinen R; Julkunen M; Seppälä M
    Hum Reprod; 1994 Dec; 9(12):2429-31. PubMed ID: 7714170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term evaluation of implantation of fresh and cryopreserved human embryos following ovarian stimulation with buserelin acetate-human menopausal gonadotrophin (HMG) or clomiphene citrate-HMG.
    Van der Elst J; Van den Abbeel E; Camus M; Smitz J; Devroey P; Van Steirteghem A
    Hum Reprod; 1996 Oct; 11(10):2097-106. PubMed ID: 8943509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-control study on reduced-dose depot versus daily administration of gonadotrophin-releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles.
    Gao J; Xu YW; Miao BY; Zhou CQ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1901-6. PubMed ID: 25056469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafarelin acetate for pituitary suppressions in in-vitro fertilisation cycles--a Singaporean experience.
    Loh SK; Leong NK
    Singapore Med J; 1999 Dec; 40(12):752-5. PubMed ID: 10709427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.